|
|
Post by vdexdiabetes on Jan 10, 2019 12:08:51 GMT -5
Galileo, your insights about MC are interesting. Not sure I agree with all of them. I do want to comment on the one area I can speak authoritatively about: VDEX. MC has made several similar comments about VDEX in other venues. I don't know where he gets his information but here are the facts: VDEX did indeed start 3+ years ago. We had no roadmap and sought to create a new kind of medical practice in the field of diabetes. The project has been more involved, more difficult, more expensive and more time-consuming than we thought at the outset. We have persevered and have validated our premise about the utility of Afrezza as a treatment for diabetes. We have also established a profitable medical practice in New Mexico featuring revolutionary protocols that result in unprecedented levels of control of blood sugar with no problems of hypoglycemia. I'm not sure what MC means in saying we've been unable to establish a successful proof of concept.
|
|
|
|
Post by sportsrancho on Jan 10, 2019 12:14:43 GMT -5
Al would be proud 👍🏻
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 10, 2019 12:36:17 GMT -5
Stevil - EVERY doctor? I highly, highly doubt this. How many doctors have you spoken to? Yes, every doctor I’ve spoken to that had heard of Afrezza. I have not yet run into a prescriber of Afrezza. On the flip side, the blank slates I’ve talked to, the ones I get to make the first impression on, say they’re impressed and they’ll follow the story once it gets better insurance coverage. The presentation I gave generated a lot of interest because I got to present Afrezza the right way. I showed why a faster insulin was needed by showing how much more area is under the curve of RAAs, why postprandial excursions are so vital to A1c, and how Afrezza could radically transform treatment with its tight control. I’ve probably spoken to 30 or so doctors about Afrezza. I’d say around 40% had heard of it. So, around 12 gave that opinion. I have yet to meet a doctor who both had heard of Afrezza and had a high opinion of it. Which is a shame because a couple were really interested in diabetes treatment and spent considerable time researching Afrezza. They came away unimpressed with the data that’s floating around out there. Stevil, in about 18 months the flood gates are going to open on CGMs. Abbott's Libre already has 1 million users and Dexcom is working on a new sensor that is smaller, thinner and less expensive that the G6 (which is a very good product). In addition to the T1 market, the new sensor will have applications for T2 as well as prediabetes, gestational and inpatient and they are partnered with Verily (Google's health arm). My belief is Amazon will get into the game too. In short, once enough patients are wired up with CGMs, the fact that most are poorly controlled will be glaring and it will become well known that the standard of care is substandard. Time in range and reducing peaks and valleys in blood glucose levels are the pieces of information that a CGM can provide. A1c is going the way of the buggy whip. In a fee for outcomes world, guess how much the doc gets for a patient with poor control of blood glucose levels? |
|
|
|
Post by liane on Jan 10, 2019 13:05:10 GMT -5
Not sure where Lakers got this quote from MC but if true, it displays a shocking level of ignorance. I don’t know how a doctor can say a drug is niche after it beats the standard of care in post Prandial and showed low rates of hypo. This guy is the CEO? Really!? Does he not know that most of the published info about Afrezza is unimpressive? Does he not know that doctors will not research or accept MNKD's anecdotal data? Does he not know that the standard of care is well established and does not include a product like Afrezza until very late in the disease progression? No wonder the compakny is failing. I've noticed another fatal quality in MC: he never admits weakness or failure. He hasn't learned that honesty even when it cuts against us is a strength. MC's always confident publicly. I remember a quote from Warren Buffett about this type of behavior. He said the problem with the executive who lies to the public is that he eventually lies to himself in private. MC has been spinning the company's 2018 results as something other than what they are which is unadulterated failure. Why should we expect anything different in 2019? BOD wake up! galileo, You've been on this board only a couple weeks, so I don't know your history or position, but quite frankly, I'm tired of the constant berating of MC and the BOD. I question your motives.
Mike has been CEO since May 2017 - less than 2 years. He comes with a background in turning around failed drug launches. I recall hearing him speak, and he said it is never easy. And I recall him saying we wouldn't see much turnaround for maybe 3 years. What I do see is lots of important steps in the right direction; things that are not immediately evident in the sales or script count. He has been systematically paying down debt and getting us out from the clutches of Deerfield. We're gaining traction on payer formularies. Slow, but sure we're gaining awareness with docs and with patients; still a long way to go, but gaining nonetheless. He hired some great people - most notably Dr Kendall who sees the value of all the unpublished studies and will bring them to light. And Mike is making some key alliances such United that will leverage the TS platform.
Mike has done a lot, much of it quietly laying the groundwork. He is confident, but not arrogant. I've met him - he's the real deal. He understands Al Mann's vision, and he understands what a groundbreaking drug he has in his stewardship. Soon this ship will sail proudly.
|
|
|
|
Post by xanet on Jan 10, 2019 13:59:00 GMT -5
Galileo, your insights about MC are interesting. Not sure I agree with all of them. I do want to comment on the one area I can speak authoritatively about: VDEX. MC has made several similar comments about VDEX in other venues. I don't know where he gets his information but here are the facts: VDEX did indeed start 3+ years ago. We had no roadmap and sought to create a new kind of medical practice in the field of diabetes. The project has been more involved, more difficult, more expensive and more time-consuming than we thought at the outset. We have persevered and have validated our premise about the utility of Afrezza as a treatment for diabetes. We have also established a profitable medical practice in New Mexico featuring revolutionary protocols that result in unprecedented levels of control of blood sugar with no problems of hypoglycemia. I'm not sure what MC means in saying we've been unable to establish a successful proof of concept.I found that comment by MC (assuming he did make it) almost shocking. I've been quite pleased with the results I've seen coming out of VDEX. Then again, I work in the world of startups, so I've learned that most things worth doing take time. And lots of it.  |
|
|
|
Post by hellodolly on Jan 10, 2019 14:04:12 GMT -5
Not sure where Lakers got this quote from MC but if true, it displays a shocking level of ignorance. I don’t know how a doctor can say a drug is niche after it beats the standard of care in post Prandial and showed low rates of hypo. This guy is the CEO? Really!? Does he not know that most of the published info about Afrezza is unimpressive? Does he not know that doctors will not research or accept MNKD's anecdotal data? Does he not know that the standard of care is well established and does not include a product like Afrezza until very late in the disease progression? No wonder the compakny is failing. I've noticed another fatal quality in MC: he never admits weakness or failure. He hasn't learned that honesty even when it cuts against us is a strength. MC's always confident publicly. I remember a quote from Warren Buffett about this type of behavior. He said the problem with the executive who lies to the public is that he eventually lies to himself in private. MC has been spinning the company's 2018 results as something other than what they are which is unadulterated failure. Why should we expect anything different in 2019? BOD wake up! galileo , You've been on this board only a couple weeks, so I don't know your history or position, but quite frankly, I'm tired of the constant berating of MC and the BOD. I question your motives.
Mike has been CEO since May 2017 - less than 2 years. He comes with a background in turning around failed drug launches. I recall hearing him speak, and he said it is never easy. And I recall him saying we wouldn't see much turnaround for maybe 3 years. What I do see is lots of important steps in the right direction; things that are not immediately evident in the sales or script count. He has been systematically paying down debt and getting us out from the clutches of Deerfield. We're gaining traction on payer formularies. Slow, but sure we're gaining awareness with docs and with patients; still a long way to go, but gaining nonetheless. He hired some great people - most notably Dr Kendall who sees the value of all the unpublished studies and will bring them to light. And Mike is making some key alliances such United that will leverage the TS platform.
Mike has done a lot, much of it quietly laying the groundwork. He is confident, but not arrogant. I've met him - he's the real deal. He understands Al Mann's vision, and he understands what a groundbreaking drug he has in his stewardship. Soon this ship will sail proudly.
Liane... as you read, I attempted to give galileo the baseball analogy. This is not a nine inning game, not even a season. It's an investment into the future of the franchise!! MC has put together a lineup that has produced enough singles, bunts, sacrifices and hit a few doubles to garner some valuable wins and to begin to earn the respect of others. MC is an impact manager of this club and as time goes on, we will see his full potential in the years to come. |
|
|
|
Post by liane on Jan 10, 2019 14:10:33 GMT -5
hellodolly - Think 2016 Chicago Cubs!!! (Just without the 100+ year wait).
|
|
|
|
Post by wgreystone on Jan 10, 2019 14:12:44 GMT -5
Stock price is slowly crawling up. Still good time to add some shares if not done yet.
|
|
|
|
Post by mannmade on Jan 10, 2019 14:42:47 GMT -5
Rod Carew made it to the Hall of Fame hitting singles... Just sayin...😊
|
|
|
|
Post by mytakeonit on Jan 10, 2019 16:06:18 GMT -5
Whoa ... glad that the pps dropped back a penny ... don't think I could handle a 5 cent increase.
I guess the extra 2 cents will fill in for Tuesday's zero cents day. That day made no cents to me.
|
|
|
|
Post by babaoriley on Jan 10, 2019 17:12:05 GMT -5
An answer to cdf, mm, vdex, sayhey. MC: “we have over 5,000 patients in our program across 65 trials for approval and most of the posters and presentations are on the corporate mannkind site. I don’t know how a doctor can say a drug is niche after it beats the standard of care in post Prandial and showed low rates of hypo. However this is why diabetes outcomes haven’t changed in 20 years despite 40 new drugs and tripling cost of treatment in 5 years. We have a mealtime control problem across the world and this is the number 1 reason people aren’t getting to goal and I believe we will be the best solution. Day after day we are gaining new prescribers and experience. I have been hearing about VDEX for 3+ years and not sure why they haven’t been able to get a successful proof of concept up and running but I hope they do for the benefit of patients. DNASE is still there and we will look at it again and the CBD we aren’t in a position to discuss as it’s the partners decision and we are looking to bring more transparency around the focus of RLS in 2019. On saying sending doctors out is a waste of time I think that is a bold statement as we see the number 1 reason a doctor starts writing is bc of our reps and while not all are cranking the way we want we like the trends we are seeing and the new talent we have is excellent. Hang tight 2019 is our year!” [undisclosed, consumer driven molecule could be deduced here as CBD-based, perhaps] Not sure where Lakers got this quote from MC but if true, it displays a shocking level of ignorance. I don’t know how a doctor can say a drug is niche after it beats the standard of care in post Prandial and showed low rates of hypo. This guy is the CEO? Really!? Does he not know that most of the published info about Afrezza is unimpressive? Does he not know that doctors will not research or accept MNKD's anecdotal data? Does he not know that the standard of care is well established and does not include a product like Afrezza until very late in the disease progression? No wonder the company is failing. I've noticed another fatal quality in MC: he never admits weakness or failure. He hasn't learned that honesty even when it cuts against us is a strength. MC's always confident publicly. I remember a quote from Warren Buffett about this type of behavior. He said the problem with the executive who lies to the public is that he eventually lies to himself in private. MC has been spinning the company's 2018 results as something other than what they are which is unadulterated failure. Why should we expect anything different in 2019? BOD wake up! Galileo, you write as if you're much smarter and more knowledgeable than MC. I very much doubt that you're either. However, your writing/editing skills are very good. |
|
|
|
Post by agedhippie on Jan 10, 2019 17:13:57 GMT -5
Stevil, in about 18 months the flood gates are going to open on CGMs. Abbott's Libre already has 1 million users and Dexcom is working on a new sensor that is smaller, thinner and less expensive that the G6 (which is a very good product). In addition to the T1 market, the new sensor will have applications for T2 as well as prediabetes, gestational and inpatient and they are partnered with Verily (Google's health arm). My belief is Amazon will get into the game too. In short, once enough patients are wired up with CGMs, the fact that most are poorly controlled will be glaring and it will become well known that the standard of care is substandard. Time in range and reducing peaks and valleys in blood glucose levels are the pieces of information that a CGM can provide. A1c is going the way of the buggy whip. In a fee for outcomes world, guess how much the doc gets for a patient with poor control of blood glucose levels? I would not bet the farm on the flood gates open any time soon. This was from a budget impact paper looking at the implications of the REPLACE study: The annual cost of SMBG with 3.7 tests per day (see REPLACE) is $180 per patient, compared to $2,156 incurred per F-CGM patient, representing a cost difference of $1,976/year or $5.41/day.Note that an F-CGM like the Libre is a lot cheaper to run than than a full CGM like the Dexcom since there is no transmitter. The insurers are going to require really compelling trials to fund at that level and it's going to significantly push up the cost of buying insurance. It took literally years for them to agree to fund CGMs for Type 1 diabetics at all. I cannot see them being any quicker to fund Type 2 diabetics. There is the option for people to self-fund (some Type 1s do this for CGMs), but that is very expensive and is going to be a small group. I wait to see how fee for outcome plays out. In principle it's an obvious choice, but it requires the insurer to care what happens when the patient is off their books. |
|
|
|
Post by lennymnkd on Jan 10, 2019 17:59:41 GMT -5
Jim Cramer speaks to Dexcom Chairman and CEO Kevin Sayer about his company's latest technology and its partnerships with other tech giants like Apple.
|
|
|
|
Post by lennymnkd on Jan 10, 2019 18:00:53 GMT -5
Remember the handheld calculator $$$$
|
|
|
|
Post by Thundersnow on Jan 10, 2019 18:22:44 GMT -5
This is a marathon and not a sprint!!!
The tortoise wins the race every time!
|
|
